225 related articles for article (PubMed ID: 29807237)
1. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.
Aparicio T; Ducreux M; Faroux R; Barbier E; Manfredi S; Lecomte T; Etienne PL; Bedenne L; Bennouna J; Phelip JM; François E; Michel P; Legoux JL; Gasmi M; Breysacher G; Rougier P; De Gramont A; Lepage C; Bouché O; Seitz JF;
Eur J Cancer; 2018 Jul; 98():1-9. PubMed ID: 29807237
[TBL] [Abstract][Full Text] [Related]
2. Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies.
Patel GS; Ullah S; Beeke C; Hakendorf P; Padbury R; Price TJ; Karapetis CS
Cancer Med; 2015 Oct; 4(10):1461-71. PubMed ID: 26211512
[TBL] [Abstract][Full Text] [Related]
3. Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy.
Cybulska-Stopa B; Ługowska I; Wiśniowski R; Domagała-Haduch M; Rajczykowski M; Piejko K; Bar-Letkiewicz I; Suwiński R; Regulski K; Mackiewicz J
Contemp Oncol (Pozn); 2020; 24(1):34-41. PubMed ID: 32514236
[TBL] [Abstract][Full Text] [Related]
4. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Cremolini C; Casagrande M; Loupakis F; Aprile G; Bergamo F; Masi G; Moretto R R; Pietrantonio F; Marmorino F; Zucchelli G; Tomasello G; Tonini G; Allegrini G; Granetto C; Ferrari L; Urbani L; Cillo U; Pilati P; Sensi E; Pellegrinelli A; Milione M; Fontanini G; Falcone A
Eur J Cancer; 2017 Mar; 73():74-84. PubMed ID: 27986363
[TBL] [Abstract][Full Text] [Related]
6. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
[TBL] [Abstract][Full Text] [Related]
7. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
[TBL] [Abstract][Full Text] [Related]
8. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
[TBL] [Abstract][Full Text] [Related]
9. Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients.
Aparicio T; Gargot D; Teillet L; Maillard E; Genet D; Cretin J; Locher C; Bouché O; Breysacher G; Seitz JF; Gasmi M; Stefani L; Ramdani M; Lecomte T; Auby D; Faroux R; Bachet JB; Lepère C; Khemissa F; Sobhani I; Boulat O; Mitry E; Jouve JL;
Eur J Cancer; 2017 Mar; 74():98-108. PubMed ID: 27825697
[TBL] [Abstract][Full Text] [Related]
10. Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials.
Faron M; Pignon JP; Malka D; Bourredjem A; Douillard JY; Adenis A; Elias D; Bouché O; Ducreux M
Eur J Cancer; 2015 Jan; 51(2):166-76. PubMed ID: 25465185
[TBL] [Abstract][Full Text] [Related]
11. Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.
Martel S; Poletto E; Ferreira AR; Lambertini M; Sottotetti F; Bertolini I; Montemurro F; Bernardo A; Risi E; Zanardi E; Ziliani S; Mura S; Dellepiane C; Del Mastro L; Minisini AM; Puglisi F
Breast; 2018 Feb; 37():142-147. PubMed ID: 29161652
[TBL] [Abstract][Full Text] [Related]
12. Body mass index and prognosis of metastatic breast cancer patients receiving first-line chemotherapy.
Gennari A; Nanni O; Puntoni M; DeCensi A; Scarpi E; Conte P; Antonucci G; Amadori D; Bruzzi P
Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1862-7. PubMed ID: 23945199
[TBL] [Abstract][Full Text] [Related]
13. Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative.
Betge J; Barat A; Murphy V; Hielscher T; Van Grieken NC; Belle S; Zhan T; Härtel N; Kripp M; Bacon O; Cordes M; Kay EW; Verheul HM; Neerincx M; Hennessy B; Hofheinz RD; Gaiser T; Ylstra B; Prehn JH; Lambrechts D; Byrne AT; Ebert MP; Schulte N
Digestion; 2016; 94(3):129-137. PubMed ID: 27756074
[TBL] [Abstract][Full Text] [Related]
14. Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients.
Landre T; Maillard E; Taleb C; Ghebriou D; Guetz GD; Zelek L; Aparicio T
Int J Colorectal Dis; 2018 Aug; 33(8):1125-1130. PubMed ID: 29680896
[TBL] [Abstract][Full Text] [Related]
15. Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.
Renfro LA; Loupakis F; Adams RA; Seymour MT; Heinemann V; Schmoll HJ; Douillard JY; Hurwitz H; Fuchs CS; Diaz-Rubio E; Porschen R; Tournigand C; Chibaudel B; Falcone A; Tebbutt NC; Punt CJ; Hecht JR; Bokemeyer C; Van Cutsem E; Goldberg RM; Saltz LB; de Gramont A; Sargent DJ; Lenz HJ
J Clin Oncol; 2016 Jan; 34(2):144-50. PubMed ID: 26503203
[TBL] [Abstract][Full Text] [Related]
16. The 'real-life' impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: a large Israeli retrospective cohort study.
Hammerman A; Greenberg-Dotan S; Battat E; Feldhamer I; Bitterman H; Brenner B
Acta Oncol; 2015 Feb; 54(2):164-70. PubMed ID: 25350524
[TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenic therapies for metastatic colorectal cancer.
Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
[TBL] [Abstract][Full Text] [Related]
18. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
[TBL] [Abstract][Full Text] [Related]
19. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.
Kabbinavar FF; Hurwitz HI; Yi J; Sarkar S; Rosen O
J Clin Oncol; 2009 Jan; 27(2):199-205. PubMed ID: 19064978
[TBL] [Abstract][Full Text] [Related]
20. Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy.
Faruk Aykan N; Yildiz I; Sen F; Kilic L; Keskin S; Ciftci R; Karabulut S; Sakar B; Disci R
Med Oncol; 2013; 30(3):679. PubMed ID: 23921648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]